2015), suggesting a potential role in modulating drug- and alcohol-seeking behavior (Merchenthaler et al
Repurposing of long-acting incretin-based therapies, including the GLP-1 receptor agonist semaglutide, the dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonist tirzepatide, and the triple GLP-1/GIP/glucagon agonist retatrutide, may offer a promising strategy treating AUD
Not for human consumption, medical, veterinary, clinical, diagnostic or treatment use.
With several options available today, many patients feel confused about which one is right for them
For a broader comparison of side effect profiles, our three-way comparison guide covers the key differences
This actually makes your transition slightly easier in some ways and slightly harder in others